ATE407691T1 - Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin) - Google Patents

Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)

Info

Publication number
ATE407691T1
ATE407691T1 AT04778434T AT04778434T ATE407691T1 AT E407691 T1 ATE407691 T1 AT E407691T1 AT 04778434 T AT04778434 T AT 04778434T AT 04778434 T AT04778434 T AT 04778434T AT E407691 T1 ATE407691 T1 AT E407691T1
Authority
AT
Austria
Prior art keywords
treatment
tslp
neoplasia
diagnosis
thymic stromal
Prior art date
Application number
AT04778434T
Other languages
English (en)
Inventor
Martin Oft
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE407691T1 publication Critical patent/ATE407691T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04778434T 2003-07-18 2004-07-16 Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin) ATE407691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48826303P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
ATE407691T1 true ATE407691T1 (de) 2008-09-15

Family

ID=34079411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04778434T ATE407691T1 (de) 2003-07-18 2004-07-16 Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)

Country Status (17)

Country Link
US (3) US20050048061A1 (de)
EP (1) EP1651247B1 (de)
JP (3) JP5436753B2 (de)
AT (1) ATE407691T1 (de)
AU (1) AU2004257781B2 (de)
CA (1) CA2532595A1 (de)
CY (1) CY1108645T1 (de)
DE (1) DE602004016522D1 (de)
DK (1) DK1651247T3 (de)
ES (1) ES2313076T3 (de)
HR (1) HRP20080617T3 (de)
MX (1) MXPA06000659A (de)
NZ (1) NZ544456A (de)
PL (1) PL1651247T3 (de)
PT (1) PT1651247E (de)
SI (1) SI1651247T1 (de)
WO (1) WO2005007186A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
PT1417231E (pt) 2001-07-23 2013-07-29 Immunex Corp Linfopoietina estromal tímica humana modificada
AU2004257781B2 (en) * 2003-07-18 2009-07-16 Merck Sharp & Dohme Corp. Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin
EP1777523A1 (de) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
UA108064C2 (uk) * 2006-12-14 2015-03-25 Вектор експресії, що містить молекулу нуклеїнової кислоти, яка кодує ізольований тимусний стромальний лімфопоетичний білок (tslp) або його антигенний фрагмент
AR067045A1 (es) * 2007-06-20 2009-09-30 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (de) 2009-01-30 2010-08-04 Institut Curie TSLP fördert Immunevasion und Persistenz von Viren
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
WO2012015696A1 (en) * 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
EP2981280A2 (de) 2013-04-04 2016-02-10 IEO - Istituto Europeo di Oncologia Srl Thymus-stroma-lymphopoetin fragmente und verwendungen davon
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
AU2018248423A1 (en) 2017-04-04 2019-10-17 Loma Linda University Biologic for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
WO2000017362A1 (en) 1998-09-21 2000-03-30 Schering Corporation Human interleukin-b50, therapeutic uses
ATE362534T2 (de) * 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
MXPA02012747A (es) * 2000-06-28 2003-09-25 Amgen Inc Moleculas del receptor de linfopoietina estromica timica y sus usos.
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
CA2429343A1 (en) * 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
PT1417231E (pt) * 2001-07-23 2013-07-29 Immunex Corp Linfopoietina estromal tímica humana modificada
AU2003208888B2 (en) * 2002-02-01 2006-10-19 Merck Sharp & Dohme Llc Uses of mammalian cytokine; related reagents
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
AU2004257781B2 (en) * 2003-07-18 2009-07-16 Merck Sharp & Dohme Corp. Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin

Also Published As

Publication number Publication date
HRP20080617T3 (en) 2009-01-31
CA2532595A1 (en) 2005-01-27
PL1651247T3 (pl) 2009-04-30
ES2313076T3 (es) 2009-03-01
AU2004257781B2 (en) 2009-07-16
PT1651247E (pt) 2008-12-15
MXPA06000659A (es) 2006-03-30
US8822405B2 (en) 2014-09-02
JP2007314547A (ja) 2007-12-06
DE602004016522D1 (de) 2008-10-23
US20100015132A1 (en) 2010-01-21
WO2005007186A1 (en) 2005-01-27
JP2011236252A (ja) 2011-11-24
US20140370025A1 (en) 2014-12-18
US20050048061A1 (en) 2005-03-03
CY1108645T1 (el) 2014-04-09
AU2004257781A1 (en) 2005-01-27
SI1651247T1 (sl) 2009-02-28
EP1651247A1 (de) 2006-05-03
EP1651247B1 (de) 2008-09-10
DK1651247T3 (da) 2009-01-12
JP5436753B2 (ja) 2014-03-05
JP2007534623A (ja) 2007-11-29
NZ544456A (en) 2009-02-28

Similar Documents

Publication Publication Date Title
ATE407691T1 (de) Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
EP2298813A3 (de) Monoklonale Antikörper gegen TRKB und Anwendungen davon
ATE440864T1 (de) Verwendung von il-23-antagonisten; verwandte reagenzien
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
BRPI0519430A2 (pt) hormânio do crescimento humano modificado
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
EA201000491A1 (ru) Аминометилзамещенные тетрациклиновые соединения
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
UY27927A1 (es) Antagonistas del receptor muscarínico m3 de acetilcolina
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DE60229643D1 (de) Zusammensetzung zur färbung von menschlichen keratd dikationische verbindungen
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
NO20055741L (no) Nye kjemiske forbindelser
EA200701293A1 (ru) Терапевтическая композиция фактора роста кератиноцитов
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
AR024114A1 (es) Antigeno (c42) asociado a tumores
EA200700949A1 (ru) Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике
ATE299739T1 (de) Neurokinin b vorläufer aus menschlicher plazenta
DE60336504D1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1651247

Country of ref document: EP